Clinical trials: Encephalitis
Japanese Encephalitis
Flavivirus Cross-priming Potential of IMOJEV
There is a pressing need for a better experimental system to understand flavivirus antibody responses, beyond dengue, to make sure the investigators are using current vaccines to greatest effect and to inform the development of…
- Trial name
- FlaviPrime (NCT03920111)
- Testing
- IMOJEV
- Where
- United Kingdom
- Volunteers
- 19 people, healthy volunteers welcome
- Sponsor
- University of Liverpool
Japanese Encephalitis
Comparison of Three Batches of the Japanese Encephalitis Vaccine IC51
The objective is to demonstrate equivalence of three IC51 batches in terms of Geometric Mean Titers for anti-JEV neutralizing antibody.
- Trial name
- NCT00594958
- Testing
- IC51
- Volunteers
- 639 people, healthy volunteers welcome
- Sponsor
- Valneva Austria GmbH
Japanese Encephalitis
Immunogenicity Study of the Japanese Encephalitis Vaccine IC51
The objective is to demonstrate the non-inferiority of the Japanese Encephalitis vaccine IC51 compared to JE-VAX in healthy subjects aged > or = 18 years
- Trial name
- NCT00604708
- Testing
- IC51, JE-VAX
- Volunteers
- 867 people, healthy volunteers welcome
- Sponsor
- Valneva Austria GmbH
Japanese Encephalitis
Safety and Tolerability of the Japanese Encephalitis Vaccine IC51
The objective is to investigate the safety and tolerability of Japanese Encephalitis vaccine IC51 with an inactive control in healthy subjects aged > or = 18 years
- Trial name
- NCT00605085
- Testing
- Japanese Encephalitis purified inactivated vaccine (IC51)
- Volunteers
- 2,675 people, healthy volunteers welcome
- Sponsor
- Valneva Austria GmbH
Encephalitis, Tick-Borne
Immunogenicity, Safety and Interchangeability of Two Tbe Vaccines Administered According to a Conventional Schedule in Children
The objective of this study is to assess the immunogenicity, safety and interchangeability of two different TBE vaccines in children aged 1-11 years, the first and second vaccination with either FSME-IMMUN 0.25ml Junior or…
- Trial name
- NCT00840801
- Testing
- Tick-Borne Encephalitis (TBE) Vaccine (Inactivated)
- Where
- 8 sites in Austria, Czechia
- Volunteers
- 302 people, healthy volunteers welcome
- Sponsor
- Pfizer
Tick-Borne Encephalitis
Study to Evaluate the Immunogenicity, Safety, and Tolerability of a Tick-Borne Encephalitis (TBE) Vaccine in Healthy Japanese Participants 1 Year of Age and Older
The main purpose of this study is to provide safety and immunogenicity data in Japanese participants.
- Trial name
- NCT04648241
- Testing
- TBE vaccine 0.5 mL, TBE vaccine 0.25 mL
- Where
- 6 sites in Japan
- Volunteers
- 165 people, healthy volunteers welcome
- Sponsor
- Pfizer
Japanese Encephalitis, Varicella
Study of Japanese Encephalitis Chimeric Virus Vaccine (JE-CV) in Children Previously Immunized With JE-CV
The aim of the study is to investigate the memory immune response and the yearly persistence of the immunity against Japanese Encephalitis (JE) after vaccination with Japanese Encephalitis Chimeric Virus Vaccine (JE-CV) in…
- Trial name
- NCT01190228
- Testing
- JE-CV Vaccine, Varicella Vaccine
- Where
- Philippines
- Volunteers
- 454 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Japanese Encephalitis
Study of a Booster Dose of IMOJEV® One Year After Primary Immunization in Healthy Children in South Korea
The aim of this study was to document the immunogenicity and safety of a booster dose of IMOJEV administered at least 12 months after the primary dose.
- Trial name
- NCT01900444
- Testing
- IMOJEV
- Where
- 8 sites in South Korea
- Volunteers
- 119 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Japanese Encephalitis
Study of a Single Primary Dose Live Attenuated Japanese Encephalitis Chimeric Virus Vaccine (IMOJEV®) in Healthy Subjects
The purpose of this study is to describe the immunogenicity and safety of IMOJEV® in adult and pediatric populations in Vietnam and serve a bridging study to compare immunogenicity, reactogenicity, and safety data obtained with…
- Trial name
- NCT02492165
- Testing
- Live attenuated Japanese encephalitis chimeric virus vaccine (IMOJEV®)
- Where
- Vietnam
- Volunteers
- 250 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Tick Borne Encephalitis
Humoral and Cellular Immunity for TBE Vaccination in Allogeneic HSCT Recipients
Patients undergoing allogeneic blood and marrow transplantation (HSCT) experience a prolonged period of dysfunctional immunity. Systematic reimmunization is necessary at appropriate time intervals following transplantation to…
- Trial name
- NCT01991067
- Testing
- TBE virus vaccine
- Where
- Austria
- Volunteers
- 34 people, healthy volunteers welcome
- Sponsor
- Medical University of Vienna
Tick Borne Encephalitis, Virus Diseases
Study to Evaluate Long Term Immunogenicity up to 10 Years After the First Booster Immunization With Tick Borne Encephalitis Vaccine in Adults Who Received 1 of 3 Different Primary Vaccination Schedules
The aim of this study is to investigate the immunogenicity response in adults up to 10 years after one booster dose. Data collected from this study will allow for greater information to prescribers who administer TBE vaccine, so…
- Trial name
- NCT01562444
- Testing
- Blood draw
- Where
- Czechia
- Volunteers
- 206 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Encephalitis
Safety and Immunogenicity of the Japanese Encephalitis Vaccine IC51 (IXIARO®) in a Pediatric Population
The primary objective is to assess the systemic and local safety profile of purified inactivated Japanese Encephalitis Virus (JEV) vaccine IC51 administered in two doses in a 28 days interval up to Month 7 after the first IC51…
- Trial name
- NCT01041573
- Testing
- IC51 Japanese Encephalitis, Havrix®720, Prevnar
- Where
- 2 sites in Philippines
- Volunteers
- 1,869 people, healthy volunteers welcome
- Sponsor
- Valneva Austria GmbH
Venezuelan Equine Encephalitis, Western Equine Encephalitis
VRC 313: A Trivalent Virus-like Particle (VLP) Encephalitis Vaccine (WEVEE) in Healthy Adults
Western Equine Encephalitis Virus (WEEV), Eastern Equine Encephalitis Virus (EEEV), and Venezuelan Equine Encephalitis Virus (VEEV) are transmitted to humans by infected mosquitoes and can cause encephalitis (swelling of the…
- Conditions
- Venezuelan Equine Encephalitis, Western Equine Encephalitis, Eastern Equine Encephalitis, Alphavirus Infections
- Trial name
- NCT03879603
- Testing
- VRC-WEVVLP073-00-VP, VRC-GENMIX083-AL-VP
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Encephalitis, Japanese
Long-term Immunogenicity After Receipt of JE Vaccine and Antibody Response and Safety to a Booster Dose
This study aims to understand the persistence of the Japanese encephalitis (JE) antibody response in previously vaccinated children.
- Trial name
- NCT02514746
- Testing
- Live Attenuated Japanese Encephalitis SA-14-14-2 Vaccine
- Volunteers
- 561 people, healthy volunteers welcome
- Sponsor
- PATH
Encephalitis, Japanese, Measles
Immunogenicity and Safety of Japanese Encephalitis Vaccine When Given With Measles-Mumps-Rubella (MMR) Vaccine
This study aims to provide evidence that co-administration of measles-mumps-rubella vaccine (MMR) and live attenuated SA 14-14-2 Japanese encephalitis vaccine (CD-JEV) does not adversely affect immunogenicity or safety.
- Conditions
- Encephalitis, Japanese, Measles, Mumps, Rubella
- Trial name
- NCT02880865
- Testing
- Live attenuated SA 14-14-2 Japanese Encephalitis vaccine, Measles, mumps, rubella vaccine
- Where
- Philippines
- Volunteers
- 628 people, healthy volunteers welcome
- Sponsor
- PATH
Encephalitis
Immunogenicity and Safety of the Japanese Encephalitis Vaccine IC51 (IXIARO®, JESPECT®) in a Pediatric Population in Non-endemic Countries
The primary objective is to assess the safety profile of IC51 in a pediatric population from regions where JEV is not endemic
- Trial name
- NCT01047839
- Testing
- IC51
- Where
- 10 sites in United States, Australia and 3 more
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Valneva Austria GmbH
Japanese Encephalitis
Boosterability of Live Attenuated Japanese Encephalitis (JE) Vaccine in Children Who Have Previously Received Inactivated JE Vaccine
To facilitate introduction of live attenuated SA 14-14-2 Japanese encephalitis vaccine (LJEV) into the National Immunization Programme of Sri Lanka, we evaluated the safety and immunogenicity of co-administration of LJEV and…
- Trial name
- NCT00463476
- Testing
- Live, Attenuated Japanese Encephalitis SA 14-14-2 Vaccine (LJEV)
- Where
- 3 sites in Sri Lanka
- Volunteers
- 305 people, healthy volunteers welcome
- Sponsor
- PATH
Japanese Encephalitis
Long Term Immunity and Safety Following Vaccination With the JEV IC51 (IXIARO®, JESPECT®) in Pediatric Population In Non Endemic Countries. Uncontrolled, Ph3 FU-Study
The study investigates long-term immunity and safety of IC51 (IXIARO®, JESPECT®) in a pediatric population vaccinated in the parent study IC51-322.
- Trial name
- NCT01246479
- Testing
- Blood draw, IC51 has given in the parent study IC51-322
- Where
- 5 sites in United States, Australia and 1 more
- Volunteers
- 23 people, healthy volunteers welcome
- Sponsor
- Valneva Austria GmbH
Encephalitis, Japanese B
Determining Safety and Efficacy of Japanese Encephalitis Vaccine When Given With Measles Vaccine
This study will determine whether it is safe and effective to administer Japanese encephalitis (JE) live attenuated SA 14-14-2 vaccine at the same time as measles vaccine.
- Trial name
- NCT00249769
- Testing
- Live Japanese encephalitis vaccine SA 14-14-2 (LJEV), Measles Vaccine (MV)
- Where
- Philippines
- Volunteers
- 600 people, healthy volunteers welcome
- Sponsor
- PATH
Eastern Equine Encephalitis
Safety and Immunogenicity Study of Eastern Equine Encephalitis (EEE) Vaccine
This study is designed to determine the safety and immunogenicity of Eastern Equine Encephalitis (EEE) Vaccine.
- Trial name
- EEE (NCT00584805)
- Testing
- Inactivated, Dried, TSI-GSD 104, EEE
- Where
- United States
- Volunteers
- 138 people, healthy volunteers welcome
- Sponsor
- U.S. Army Medical Research and Development Command